Actively Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Led by Nurix Therapeutics, Inc. · Updated on 2026-03-20
248
Participants Needed
16
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
CONDITIONS
Official Title
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 18 years of age or older
- Have measurable disease per disease-specific response criteria
- Indolent non-Hodgkin lymphoma patients must meet criteria requiring systemic treatment
- Patients with transformed lymphoma are eligible except those with specified aggressive MCL types or known TP53 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for non-PCNSL or 0 to 2 for PCNSL patients
- Adequate organ and bone marrow function
- Patients of child-bearing potential must use effective contraception during the study
- For Phase 1a: Histologically confirmed relapsed/refractory CLL, SLL, WM, MCL, MZL, FL, DLBCL, or PCNSL
- Received at least 2 prior systemic therapies (or at least 1 prior therapy for WM or PCNSL) with no known beneficial therapies remaining
- Must require systemic therapy
- For Phase 1b: Histologically documented relapsed/refractory B-cell malignancies meeting specific prior treatment failure criteria per disease type
You will not qualify if you...
- Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
- Known or suspected other autoimmune diseases except certain controlled conditions like alopecia or hypothyroidism
- Unable to swallow capsules or conditions interfering with drug delivery or absorption
- Bleeding disorders or known risk of acute blood loss
- Ongoing treatment with warfarin or similar vitamin K antagonists within 7 days before first dose
- Prior radiotherapy within 2 weeks before study drug start (except limited palliative radiation)
- Unresolved toxicities from previous cancer therapies above Grade 1 except specific exceptions
- Active known second malignancy except non-metastatic, non-melanoma skin cancer
- Major surgery within 4 weeks before planned first dose
- HIV infection unless well controlled with adequate immune status
- Active liver disease of any cause
- Active viral reactivation such as CMV or EBV
- Use of systemic corticosteroids exceeding defined doses within specified timeframes
- Use of non-steroidal immunosuppressive drugs within 30 days prior to study start
- Clinically significant uncontrolled cardiac or cardiovascular disease or recent myocardial infarction
- Use of strong CYP3A inducers/inhibitors or P-glycoprotein inhibitors within specified periods before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
University of California Irvine
Orange, California, United States, 92868
Completed
3
University of California San Francisco Medical Center
San Francisco, California, United States, 94143
Completed
4
Sarah Cannon Research Institute at Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
5
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140
Completed
6
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, United States, 34203
Completed
7
The University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
8
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20814
Actively Recruiting
9
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Completed
10
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
Completed
11
OSU Wexner Medical Center
Columbus, Ohio, United States, 43210
Completed
12
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
13
Baylor University Medical Center
Dallas, Texas, United States, 75246
Completed
14
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
15
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
16
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Completed
Research Team
P
Patient Outreach
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
11
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here